Uncategorized Archives

NVIDIA’s AI Empire Expands Beyond the Cloud and Sovereign AI May Be the Next Frontier -( $AMZN $APO $BLK $BX $GS $NVDA )

by John F. Heerdink, Jr. 1 day ago 201Views 0Likes

NVIDIA’s blockbuster fiscal Q2 2027 earnings reinforced its position at the center of the global AI infrastructure boom. With record data-center revenue, accelerating demand for Blackwell and Vera Rubin systems, and a rising sovereign-AI opportunity, NVIDIA (NASDAQ: NVDA) is expanding from GPU…

Tariff Refunds, Rate Relief and Silicon Valley’s Staying Power Set a Constructive Stage for Investors -( $AAPL $AMZN $FDX $HD $LOW $NVDA $TGT $TJX $WMT )

by John F. Heerdink, Jr. August 20, 2026 272Views 0Likes

A volatile tape has produced an unexpectedly investable combination: major retailers are receiving fresh tariff refunds, mortgage rates have edged lower, and the debate around California’s proposed wealth tax underscores rather than erases Silicon Valley’s enduring economic gravity. For investors, the message…

Heartflow’s AI-Cardiology Moment Arrives as Consumer Cyclicals Catch Their Breath -( $AMWL $HD $HTFL $LOW $TGT $WMT )

by John F. Heerdink, Jr. August 17, 2026 242Views 0Likes

Heartflow, Inc. (NASDAQ: HTFL) is delivering the kind of growth story investors usually hope to find before it becomes obvious: rapid revenue expansion, rising gross margins, stronger adoption of a second product line, and a materially higher full-year outlook. In a market…

S&P 500 Extends Record Run While Producer Prices Forget to Inflate – Thursday, August 13, 2026 -( $AMWL $DOCS $EPRX $HPP $NVDA $SMCI $YSG Rise! )

by John F. Heerdink, Jr. August 13, 2026 258Views 0Likes

U.S. stocks finished broadly higher on Thursday, August 13, as investors welcomed a benign producer-inflation report and maintained confidence in the large-cap technology and artificial-intelligence growth narrative. All four major U.S. equity benchmarks—the S&P 500, Dow Jones Industrial Average, Nasdaq Composite, and…

Biotech’s Bullish Blueprint: Jazz Pharmaceuticals Buys Actio For ~$1.3B, While Eupraxia Builds for Scale -( $EPRX $JAZZ $XBI )

by John F. Heerdink, Jr. August 11, 2026 157Views 0Likes

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) and Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX) offer investors two distinctly attractive versions of the same biotech proposition: value creation through disciplined execution. Jazz is deploying capital to deepen an established rare-epilepsy franchise, while Eupraxia is assembling the…

Eli Lilly-Backed Scribe Therapeutics Stuns Wall Street With a Rare Gene-Editing IPO -( $LLY $SCTX $SNY )

by John F. Heerdink, Jr. July 25, 2026 265Views 0Likes

Eli Lilly-backed Scribe Therapeutics is having the kind of debut that makes Wall Street reach for a second coffee: the CRISPR company priced an upsized IPO, then saw its shares jump sharply in trading, a rare show of enthusiasm for an early-stage…

Cash, Catalysts and Credentials: Why Agenus and Eupraxia Are Starting to Screen In -( $AGEN $EPRX $XBI )

by John F. Heerdink, Jr. July 13, 2026 283Views 0Likes

Agenus Inc. (NASDAQ: AGEN) and Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX, TSX: EPRX) just offered Wall Street a reminder that in biotech, capital and human capital still set the tempo—one via an oversubscribed private placement, the other via a board refresh that reads…

Biotech Sizzles While Beef Soars: Why Investors Are Buying Labs, Not Ribeyes -( $AMWL $EPRX $MODD $XBI )

by John F. Heerdink, Jr. July 11, 2026 332Views 0Likes

Beef is getting pricier just as biotech is getting hotter, and for investors willing to look past the grocery aisle to the lab bench, that may be the more interesting inflation story. From Ribeye Shock to Risk-On: The Macro Backdrop Consumers may…

When Geopolitics Meets Gigawatts: Finding Opportunity in a World That’s Short on Power, Long on Risk -( $AMD $BP $CVX $DUK $NVDA $SPCX $VLO $XOM )

by John F. Heerdink, Jr. July 9, 2026 329Views 0Likes

Wall Street is attempting something it does well in moments of drama: turning a string of geopolitical and market plot twists into a surprisingly investable narrative. Hormuz Heats Up, Oil Wakes Up When the U.S. military launches strikes against Iranian targets near…

From Boardroom to Best Seller: Building Great Businesses in an Operators’ Market & The Magnificent Seven

by John F. Heerdink, Jr. July 6, 2026 239Views 0Likes

Wall Street’s favorite soap opera—Big Tech, Big Health and Big AI—just dropped a new episode, and the cast is in rare form: trillion‑dollar titans, rebounding payors, a USA Today best‑selling business book, and a freshly funded health‑tech upstart all sharing the stage.…

Uncategorized

Your Guide To Staying Informed In The Markets